2021
DOI: 10.1038/s41379-020-00692-8
|View full text |Cite
|
Sign up to set email alerts
|

TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

20
157
7
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 141 publications
(223 citation statements)
references
References 31 publications
20
157
7
1
Order By: Relevance
“…20,30 Our findings and recent study suggest that TRPS1 is a highly sensitive and specific marker to confirm breast origin and can be used as a great diagnostic tool, especially for TNBC including metaplastic BC. 14 In summary, this study has significantly expanded our knowledge of TRPS1 expression in BCs, especially metaplastic carcinomas, which usually lack good markers. Furthermore, we have also documented TRPS1's expression in normal breast ductal epithelial cells and TRPS1's potential cross-reactivity with HER2 protein.…”
Section: Discussionmentioning
confidence: 79%
See 1 more Smart Citation
“…20,30 Our findings and recent study suggest that TRPS1 is a highly sensitive and specific marker to confirm breast origin and can be used as a great diagnostic tool, especially for TNBC including metaplastic BC. 14 In summary, this study has significantly expanded our knowledge of TRPS1 expression in BCs, especially metaplastic carcinomas, which usually lack good markers. Furthermore, we have also documented TRPS1's expression in normal breast ductal epithelial cells and TRPS1's potential cross-reactivity with HER2 protein.…”
Section: Discussionmentioning
confidence: 79%
“…A recent study has demonstrated that TRPS1 is a highly sensitive and specific marker for BCs with comparable positive expression to GATA3 in ER + and HER2 + BCs, but significantly higher expression than GATA3 in TNBCs using TMAs. 14 To further explore TRPS1's utility in BCs, we systematically evaluated TRPS1 expression in 160 ER + /HER2 + BCs, 94 ER − /HER2 + BCs, 117 TNBCs, and 618 other primary carcinomas including 93 endometrial carcinomas, 109 cholangiocarcinomas, 208 colorectal adenocarcinomas, and 208 hepatocellular carcinomas by IHCs on TMAs. Furthermore, we performed TRPS1 IHC on whole tissue sections from 64 HER2 + BCs, 76 TNBCs, and 67 invasive metaplastic BCs and compared its expression with GATA3.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, ultrasound endoscopy can also determine the cystic solidity of the tumour by its echogenicity [ 12 ]. In addition, ultrasound endoscopy can also determine the cystic solidity of the tumour by its echogenicity, thus further differentiating it from some other gastric tumours [ 13 ]. However, the application of RECIST morphological criteria based only on the change of tumour size does not accurately reflect the effect of tumour treatment, and there are limitations in using it to evaluate the targeted treatment of gastrointestinal mesenchymal tumours [ 14 ].…”
Section: Related Workmentioning
confidence: 99%
“…24 In light of these difficulties, Di et al proposed the transcription factor TRPS1 as a novel biomarker for TN MpBCs, being expressed in 86% of cases relative to GATA3's 21%. 21 Genetic analysis of the patient's breast mass indicated mutations inCDH1 , raising alarm. This gene encodes E-cadherin, a transmembrane glycoprotein that maintains cell-cell adhesion.…”
Section: Discussionmentioning
confidence: 99%